| 1 |
Mentzel T, Sclerosing Katenkamp D. pseudovascular rhabdomyosarcoma in adults. Clinicopathological and immunohistochemical analysis of three cases [J].Virchows Arch, 2000, 436(4): 305-311.
|
| 2 |
Zambo I, Vesely K. WHO classification of tumors of soft tissue and bone 2013: the main changes compared to the 3rd edition [J].Cesk Patol, 2014, 50(2): 64-70.
|
| 3 |
Leiner J, Le Loarer F. The current landscape of rhabdomyosarcomas: an update [J]. Virchows Arch, 2020, 476(1): 97-108.
|
| 4 |
张瑞峰, 张庆钊, 徐芳, 等. 硬化性横纹肌肉瘤临床病理观察 [J]. 诊断病理学杂志, 2020, 27(2): 104-106.
|
| 5 |
Cessna MH, Zhou H, Perkins SL, et al. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics [J]. Am J Surg Pathol, 2001, 25(9): 1150-1157.
|
| 6 |
Mentzel T, Kuhnen C. Spindle cell rhabdomyosarcoma in adults: clinicopathological and immunohistochemical analysis of seven new cases [J]. Virchows Arch, 2006, 449(5): 554-560.
|
| 7 |
Nascimento AF, Fletcher CD. Spindle cell rhabdomyosarcoma in adults [J]. Am J Surg Pathol, 2005, 29(8): 1106-1113.
|
| 8 |
杨丽, 张红娟, 杨守京. 梭形细胞/硬化性横纹肌肉瘤20例临床病理学观察 [J]. 中华病理学杂志, 2020, 49(4): 336-342.
|
| 9 |
González-González R, Bologna-Molina R, Molina-Frechero N, et al. Prognostic factors and treatment strategies for adult head and neck soft tissue sarcoma [J]. Int J Oral Maxillofac Surg, 2012, 41(5): 569-575.
|
| 10 |
Ku JY, Roh JL, Cho, KJ, et al. Risk factors for survival of head and neck soft tissue sarcomas: a comparison between 7th and 8th edition AJCC staging systems [J]. Oral Oncol, 2020, 106(1): 104705.
|
| 11 |
Lee NCJ, Eskander A, Miccio JA, et al. Evaluation of head and neck soft tissue sarcoma 8th edition pathologic staging system and proposal of a novel stage grouping system [J]. Oral Oncol, 2021, 114(1): 105137.
|
| 12 |
Kato MA, Flamant F, Terrier-Lacombe MJ, et al. Rhabdomyosarcoma of the larynx in children: a series of five patients treated in the Institut Gustave Roussy (Villejuif, France) [J]. Med Pediatr Oncol, 1991, 19(2): 110-114.
|
| 13 |
刘欣, 张晓伟, 王惠杰, 等. 聚乙二醇化脂质体多柔比星联合异环磷酰胺治疗晚期转移性软组织肉瘤 [J]. 中国癌症杂志, 2017, 27(9): 687-692.
|
| 14 |
Van Erp AEM, Versleijen-Jonkers YMH, Van der Graaf WTA, et al. Targeted therapy-based combination treatment in rhabdomyosarcoma [J]. Mol Cancer Ther, 2018, 17(7): 1365-1380.
|
| 15 |
Komuro H, Saihara R, Shinya M, et al. Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines [J]. J Pediatr Surg, 2007, 42(12): 2040-2045.
|
| 16 |
Salerno M, Avnet S, Bonuccelli G, et al.Impairment of lysosomal activity as a therapeutic modality targeting cancer stem cells of embryonal rhabdomyosarcoma cell line RD [J]. PLoS One, 2014, 9(10): e110340.
|
| 17 |
Ishi Y, Yamaguchi S, Iguchi A, et al. Primary pineal rhabdomyosarcoma successfully treated by high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation: case report [J]. J Neurosurg Pediatr, 2016, 18(1): 41-45.
|
| 18 |
Yamazaki F, Osumi T, Shigematsu N, et al.Successful treatment of metastatic rhabdomyosarcoma with radiochemotherapy and allogeneic hematopoietic stem cell transplantation [J]. JPN J Clin Oncol, 2015, 45(2): 225-228.
|
| 19 |
Zhao B, Yang C, Yang S, et al. Construction of conditional lentivirus-mediated shRNA vector targeting the human Mirk gene and identification of RNAi efficiency in rhabdomyosarcoma RD cells [J]. Int J Oncol, 2013, 43(4): 1253-1259.
|
| 20 |
Krukemeyer M, Krenn V, Jakobs M, et al. Magnetic drug targeting in a rhabdomyosarcoma rat model using magnetite-dextran composite nanoparticle-bound mitoxantrone and 0.6 tesla extracorporeal magnets-sarcoma treatment in progress [J]. J Drug Target, 2012, 20(2): 185-193.
|
| 21 |
Grabarska A, Skalicka-Wozniak K, Kielbus M, et al. Imperatorin as a promising chemotherapeutic agent against human larynx cancer and rhabdomyosarcoma cells [J]. Molecules, 2020, 25(9): 2046.
|
| 22 |
Esnaola NF, Rubin BP, Baldini EH, et al. Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma [J]. Ann Surg, 2001, 234(2): 215-223.
|
| 23 |
Ferrari A, Miceli R, Meazza C, et al. Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma [J]. J Clin Oncol, 2010, 28(8): 1322-1328.
|
| 24 |
Agaram NP, Chen CL, Zhang L, et al. Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis [J]. Genes Chromosomes Cancer, 2014, 53(9): 779-787.
|
| 25 |
Alaggio R, Zhang L, Sung YS, et al. A molecular study of pediatric spindle and sclerosing rhabdomyosarcoma: identification of novel and recurrent VGLL2-related fusions in infantile cases [J]. Am J Surg Pathol, 2016, 40(2): 224-235.
|
| 26 |
Owosho AA, Chen S, Kashikar S, et al. Clinical and molecular heterogeneity of head and neck spindle cell and sclerosing rhabdomyosarcoma [J]. Oral Oncol, 2016, 58: e6-e11.
|
| 27 |
Agaram NP, LaQuaglia MP, Alaggio R, et al. MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification [J]. Mod Pathol, 2019, 32(1): 27-36.
|
| 28 |
Owosho AA, Huang SC, Chen S, et al. A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome [J]. Oral Oncol, 2016, 61: 89-97.
|
| 29 |
Gorunova L, Bjerkehagen B, Micci F, et al. Cytogenetic and molecular study of an adult sclerosing rhabdomyosarcoma of the extremity: MYOD1-mutation and clonal evolution [J]. Cancer Genomics Proteomics, 2020, 17(5): 563-569.
|
| 30 |
Dikbas O, Altundag K, Abali H, et al. Embryonal rhabdomyosarcoma of the larynx [J]. Otolaryngol Head Neck Surg, 2005, 133(1): 160-162.
|
| 31 |
杨征, 房居高, 钟琦, 等. 成人喉部横纹肌肉瘤临床分析 [J]. 中国耳鼻咽喉头颈外科, 2017, 24(6): 275-278.
|